NSE: MANKIND | BSE: 543904

Expensive Performer

Download real time

2206.30 0.70 (0.03%)

Near 52W Low of ₹2115.10

418.3K NSE+BSE Volume

NSE 04 Dec, 2025 3:31 PM (IST)

91,077.2

Market Cap

High in industry

Beta 1Year

Very Low volatility

Mankind Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for MANKIND, BSE:543904 Mankind Pharma Ltd.

Search Inside the pdf :

Mankind Pharma Ltd.

26 Nov 2025

2206.30

0.03%

MANKIND PHARMA LIMITED

Buy: Mankind Pharma Ltd.

Recommendation Target

Geojit BNP Paribas

*over or under performance to benchmark index Mankind Pharma is an Indian multinational pharmaceutical and healthcare product company, headquartered in New Delhi. The company has products in therapeutic areas...

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

07 Nov 2025

2206.30

0.03%

2Q in line; transition phase underway

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered a largely in-line financial performance for 2QFY26. EBITDA was slightly lower than estimates due to higher employee costs.

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

01 Aug 2025

2206.30

0.03%

Cost headwinds lead to earnings miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) reported in-line revenue in 1QFY26. However, EBITDA/PAT came in 5%/7% below our estimates.

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

22 May 2025

2206.30

0.03%

Higher marketing/promotional costs drive a miss

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

26 Mar 2025

2206.30

0.03%

MANKIND PHARMA LIMITED

Accumulate: Mankind Pharma Ltd.

Geojit BNP Paribas

Mankind Pharma Ltd. has an average target of 2700.00 from 2 brokers.

Mankind Pharma Ltd.

25 Jan 2025

2206.30

0.03%

Laurus Lab (LAURUS) significantly beat our earnings estimates in 3QFY25, led by a scale-up in the CDMO segment. Commercial supplies (including launch quantities) led to strong 89% YoY growth in CDMO sales for the quarter.

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (Mankind) delivered in-line operational performance for 3QFY25. The earnings were below estimates due to higher interest outgo on debt raised to fund the BSV acquisition.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

05 Nov 2024, 12:00AM

2206.30

0.03%

Superior execution in consumer wellness/exports drives beat on 2Q estimates

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business.

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

23 Aug 2024

2206.30

0.03%

FundsIndia

Mankind Pharma Ltd. is trading below all available SMAs

Mankind Pharma Ltd.

23 Aug 2024

2206.30

0.03%

Improvising the base; adding new avenues for growth

Buy: Mankind Pharma Ltd.

Target

Motilal Oswal

MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-the counter (OTC) space.

Number of FII/FPI investors decreased from 648 to 627 in Sep 2025 qtr

Mankind Pharma Ltd.

26 Jul 2024

2206.30

0.03%

Unlocking new vertical through BSV acquisition

Buy: Mankind Pharma Ltd.

Motilal Oswal

Mankind Pharma has agreed to acquire Bharat Serum Vaccines (BSV) for EV of INR136b, implying EV/EBITDA of 28x/22-23x on FY24/FY25 basis.

Geojit BNP Paribas upgraded Mankind Pharma Ltd. to Buy with a price target of 2600.0 on 26 Nov, 2025.